Form 4: HCA Exec Exercises SARs, Sells Shares

HCA Healthcare's EVP & Chief Legal & Administrative Officer, Michael R. McAlevey, exercised stock appreciation rights and subsequently sold a portion of the acquired shares.

Summary

• Michael R. McAlevey, EVP & Chief Legal & Administrative Officer of HCA Healthcare, Inc., reported transactions involving company stock.
• On February 13, 2026, McAlevey exercised 5,000 Stock Appreciation Rights (SARs) with an exercise price of $236.61 per share.
• Concurrently, 3,306 shares of Common Stock were disposed of at $540.29 per share to cover tax obligations related to the SAR exercise.
• On February 18, 2026, an additional 1,694 shares of Common Stock were sold at an average price of $533.3747 per share.
• Following these transactions, McAlevey directly owns 8,853 shares of Common Stock, indirectly owns 2,111 shares through a 2024 GRAT, and 26 shares through a managed account.
• The Stock Appreciation Rights vested in four equal annual installments beginning on January 28, 2023.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine executive compensation event, reflecting the realization of value from previously granted stock appreciation rights. The sale of shares is typical for tax purposes and portfolio diversification.

Positives

• The executive realized a significant gain from the exercise of Stock Appreciation Rights, as the market price at the time of disposition ($540.29 and $533.3747) was substantially higher than the SAR exercise price ($236.61).
• The transactions demonstrate the effectiveness of the company's executive compensation plan in aligning management incentives with shareholder value creation.

Negatives

• The executive reduced direct beneficial ownership of Common Stock by 1,694 shares through a market sale, in addition to shares withheld for taxes.

Risks

• No specific company-level risks are detailed in this Form 4 filing, which focuses solely on individual insider transactions.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly the exercise of stock appreciation rights and subsequent sales for tax purposes or diversification, are common occurrences for executives in the healthcare industry and across public companies. These transactions are often pre-planned under Rule 10b5-1 plans to avoid accusations of trading on material non-public information.

Comparison to Industry Standards

• The exercise of Stock Appreciation Rights (SARs) and subsequent "sell-to-cover" transactions for tax obligations are standard practices in executive compensation across various industries, including healthcare.
• The reported transaction values and volumes are consistent with typical compensation-related activities for an executive at a large-cap healthcare provider like HCA Healthcare, Inc., which operates hospitals and healthcare facilities comparable to Universal Health Services (UHS) or Tenet Healthcare (THC).
• The structure of SARs vesting over several years, as seen with the January 28, 2023, vesting start date, is a common long-term incentive mechanism designed to retain executives and align their interests with sustained company performance.

Related Party Transactions

• 2,111 shares of Common Stock are indirectly owned by a 2024 GRAT (Grantor Retained Annuity Trust), which is a common estate planning vehicle for executives.
• 26 shares of Common Stock are indirectly owned through a fully managed account, over which the reporting person disclaims investment authority.

Stakeholder Impact

• Shareholders: Minimal direct impact, as these are routine compensation-related insider transactions and do not indicate a significant shift in company fundamentals or executive sentiment beyond the ordinary course of business.

Key Dates

Recommendation

This Form 4 details a routine executive compensation event involving the exercise of stock appreciation rights and subsequent share sales for tax and diversification purposes. It does not present new information that would alter the fundamental investment thesis for HCA Healthcare, thus a 'hold' recommendation remains appropriate.

Keywords

HCA Healthcare, HCA, insider trading, Form 4, stock appreciation rights, SARs, executive compensation, share sale